Clinical trials: Follicular Lymphomas
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Pre-clinical data and recently published clinical data suggest a synergistic effect between lenalidomide and dexamethasone. We hypothesize that a combination of lenalidomide-dexamethasone can overcome rituximab resistance.
- Conditions
- Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT00783367
- Testing
- Lenalidomide, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- REFINE-1 (NCT01542034)
- Testing
- Deoxycholic acid injection
- Where
- 36 sites in United States, Canada
- Volunteers
- 506 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Sedentary Lifestyle, Dementia, Mild
Smartphone App to Improve Physical Activity in Older Adults With MCI/Mild Dementia
The purpose of this study is to develop and test a physical activity-tracking smartphone app designed to facilitate physical activity in older adults with mild cognitive impairments or mild dementia.
- Conditions
- Sedentary Lifestyle, Dementia, Mild, Mild Cognitive Impairment, Memory and Thinking Problems
- Trial name
- NCT04950998
- Testing
- Moving Up - A
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Follicular Lymphoma, Small Lymphocytic Lymphoma
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT03828448
- Testing
- Ublituximab, Umbralisib
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- TG Therapeutics, Inc.
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00012298
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
- Trial name
- LOTIS-6 (NCT04699461)
- Testing
- Loncastuximab Tesirine, Idelalisib
- Where
- 34 sites in United States, Belgium and 8 more
- Volunteers
- 6 people
- Sponsor
- ADC Therapeutics S.A.
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00290472
- Testing
- temsirolimus
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00425802
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Chronic Musculoskeletal Pain, Posttraumatic Stress Disorder (PTSD)
Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD
The wars in Iraq and Afghanistan are creating a new generation of Veterans, including an increasing number of women Veterans, who present with comorbid PTSD and chronic pain conditions from recent deployment-related physical…
- Conditions
- Chronic Musculoskeletal Pain, Posttraumatic Stress Disorder (PTSD), Mild or Moderate Traumatic Brain Injury
- Trial name
- EXCPPTSD (NCT03283163)
- Testing
- Exercise Testing and Training
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Lymphoma, Relapsed and Refractory
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
The purpose of this study is to learn if the study drug mocetinostat can slow the progression of cancer in people who have a mutation in CREBBP or EP300 in the genetic makeup of their cancer.
- Conditions
- Lymphoma, Relapsed and Refractory, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
- Trial name
- NCT02282358
- Testing
- Mocetinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04432506
- Testing
- Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center